Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
TH Open
.
2023 Aug 28;7(3):e241-e243.
doi: 10.1055/a-2122-7887.
eCollection 2023 Jul.
Authors
Naoki Matsumoto
1
,
Hiroto Abe
1
,
Ryohei Kawasaki
1
,
Yoshihito Tashiro
1
,
Mariko Noguchi-Sasaki
1
,
Suguru Harada
1
,
Koichiro Yoneyama
2
,
Tomomi Niino
2
,
Tetsuhiro Soeda
1
,
Yasushi Yoshimura
1
Affiliations
1
Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.
2
Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan.
PMID:
37645671
PMCID:
PMC10462426
DOI:
10.1055/a-2122-7887
No abstract available